DDInter1638 DDInter927
Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Samarium (153Sm) lexidronam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Foscarnet
Samarium (153Sm) lexidronam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Altretamine
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Polatuzumab vedotin
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Altretamine
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Polatuzumab vedotin